Recurrent plasma cell myeloma Trials in Seattle, United States
Conditions / Recurrent plasma cell myeloma / Seattle, United States
Recurrent plasma cell myeloma is a medical condition with active clinical research programs worldwide.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | COMPLETED | — |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | COMPLETED | PHASE2 |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | TERMINATED | PHASE2 |
| NCT01008462 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | COMPLETED | PHASE2 |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | COMPLETED | PHASE2 |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | TERMINATED | PHASE2 |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | COMPLETED | PHASE2 |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | COMPLETED | — |